PMID- 35716269
OWN - NLM
STAT- MEDLINE
DCOM- 20220909
LR  - 20221109
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 29
IP  - 10
DP  - 2022 Oct
TI  - Anti-CD20 therapy for multiple sclerosis-associated uveitis: A case series.
PG  - 3028-3038
LID - 10.1111/ene.15453 [doi]
AB  - BACKGROUND AND PURPOSE: Approximately 1% of patients with multiple sclerosis (MS) 
      have uveitis, but data on the effects of immunotherapies for MS on MS-associated 
      uveitis are scarce. The aim of this study was to investigate the ophthalmological 
      outcomes in patients with MS-associated uveitis treated with anti-CD20 therapy. 
      METHODS: A retrospective study of 12 eyes of six patients with MS-associated 
      uveitis, refractory to previous immunotherapies, was conducted. Uveitis activity 
      was assessed before initiation of anti-CD20 therapy and at regular follow-up 
      visits. Primary outcome measures were: vitreous haze score; retinal vasculitis 
      score, determined on fluorescein angiography images; macular edema, as quantified 
      by central retinal thickness (CRT) on optical coherence tomography; and visual 
      acuity (VA). Secondary outcomes included number of annualized uveitis or MS 
      relapses, disease activity on cerebral magnetic resonance imaging (cMRI) and 
      Expanded Disability Status Scale (EDSS) score. RESULTS: After a median 
      (interquartile range [IQR]) treatment time of 28.5 (8-43) months, anti-CD20 
      therapy was associated with an improvement of vitreous haze score (p = 0.002), 
      retinal vasculitis score (p = 0.001), CRT (p = 0.002), and VA (p = 0.007). The 
      median (IQR) annualized uveitis relapse rate declined from 0.59 (0.56-0.94) 
      before to 0 (0-0.49) after the start of anti-CD20 therapy. The median (IQR) 
      annualized MS relapse rate declined from 0.62 (0.26-2.84) before to 0 (0-0) after 
      the start of anti-CD20 therapy. After initiation of anti-CD20 therapy, there was 
      no disease activity on cMRI, and EDSS score improved (n = 2) or remained stable 
      (n = 4). No severe adverse events were observed. CONCLUSION: These findings 
      suggest that anti-CD20 therapy may be a valuable treatment option for 
      MS-associated uveitis.
CI  - (c) 2022 The Authors. European Journal of Neurology published by John Wiley & 
      Sons Ltd on behalf of European Academy of Neurology.
FAU - Stascheit, Frauke
AU  - Stascheit F
AUID- ORCID: 0000-0001-5306-7880
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - NeuroCure Clinical Research Center, Charite - Universitatsmedizin Berlin, 
      corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Berlin, Germany.
FAU - Rubsam, Anne
AU  - Rubsam A
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, 
      Germany.
FAU - Otto, Carolin
AU  - Otto C
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
FAU - Meisel, Andreas
AU  - Meisel A
AUID- ORCID: 0000-0001-7233-5342
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - NeuroCure Clinical Research Center, Charite - Universitatsmedizin Berlin, 
      corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Berlin, Germany.
AD  - Center for Stroke Research Berlin, Charite - Universitatsmedizin Berlin, 
      corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Berlin, Germany.
FAU - Ruprecht, Klemens
AU  - Ruprecht K
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
FAU - Pleyer, Uwe
AU  - Pleyer U
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220713
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Humans
MH  - *Multiple Sclerosis/complications/diagnostic imaging/drug therapy
MH  - Neoplasm Recurrence, Local
MH  - *Retinal Vasculitis/complications
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/methods
MH  - Treatment Outcome
MH  - *Uveitis/drug therapy/etiology
OTO - NOTNLM
OT  - anti-CD20 therapy
OT  - multiple sclerosis
OT  - ocrelizumab
OT  - retinal fluorescein angiography
OT  - rituximab
OT  - uveitis
EDAT- 2022/06/19 06:00
MHDA- 2022/09/11 06:00
CRDT- 2022/06/18 11:18
PHST- 2022/04/26 00:00 [received]
PHST- 2022/06/12 00:00 [accepted]
PHST- 2022/06/19 06:00 [pubmed]
PHST- 2022/09/11 06:00 [medline]
PHST- 2022/06/18 11:18 [entrez]
AID - 10.1111/ene.15453 [doi]
PST - ppublish
SO  - Eur J Neurol. 2022 Oct;29(10):3028-3038. doi: 10.1111/ene.15453. Epub 2022 Jul 
      13.